摘要
目的探讨Ki67、GFAP与人脑恶性胶质瘤病理分级的关系。方法取深圳市宝安区中医院病理科2007年1月～2012年12月组织学确诊为恶性胶质瘤标本3l例，根据WHO（2007年）胶质瘤分级标准，分为胶质瘤Ⅱ级组、胶质瘤Ⅲ级组和胶质瘤Ⅳ级组，另取10名正常人脑组织胶质细胞作为正常对照组。免疫组织化学法检测Ki67及GFAP表达。结果Ki67表达水平在正常对照组最低，随着肿瘤WHO分级的增高而增高，在胶质瘤Ⅳ级组达高峰，差异有统计学意义（P〈0．05）；GFAP表达水平在正常对照组最高，随WHO分级的增高而降低，在胶质瘤Ⅳ级组表达水平最低，差异有统计学意义（P〈0．05）。结论Ki67、GFAP可作为人脑恶性胶质瘤病理分级及预后判断有价值的参考指标。
Objective To study the correlation betweem Ki67, GFAP expression and pathological grading of human brain malignant glioma. Methods 31 cases of malignant glioma specimens confirmed by histology in Hospital of TCM in Bao＇an District of Shenzhen City were collected from January 2007 to December 2012, while divided into glioma Ⅱ, Ⅲ and Ⅳ grade groups according to WHO （2007） glioma grading standards. Another 10 cases of normal brain tissues were selected as control group. Then the expression of Ki67, GFAP was detected by immunohistoehemistry. Results The expression of Ki67 in normal control group was the lowest, which increased with the increase of WHO grading of tumors, reached a peak in glioma Ⅳ grade group, the difference was statistically significant （P 〈 0.05）. The expression level of GFAP in normal control group was the highest, which decreased with the increase of WHO grading of tumors, reached a bottom in glioma Ⅳ grade group, the difference was statistically significant （P 〈 0.05）. Conclusion Ki67 and GFAP can be regarded as valuable markers to judge the pathological grading and prognosis.
出处
《中国医药导报》
CAS
2014年第18期31-34,共4页
China Medical Herald
基金
广东省自然科学基金面上项目(编号S2012020010882)
广东省深圳市宝安区科技计划项目(编号2013115)
